Wiley Blackwell

SHERPA: Unknown

People

  1. Herr
    Herr
  2. Brennan
    Brennan
  3. Motzer
    Motzer
  4. Shah
    Shah
  5. Danishefsky
    Danishefsky
  6. Russo
    Russo
  7. Shaha
    Shaha
  8. Vickers
    Vickers
  9. Eastham
    Eastham
  10. Mulhall
    Mulhall

Groups

  1. Department of Medicine (1520)
  2. Surgery (1224)
  3. Solid Tumor Oncology Division (883)
  4. Survivorship Research (806)
  5. GSK Faculty (664)
  6. Sloan Kettering Institute Faculty (622)
  7. Population Sciences Research Program (614)
  8. Department of Pathology and Laboratory Medicine (533)
  9. Epidemiology and Biostatistics (484)
  10. Center for Hematologic Malignancies (432)
Search Within
Formats
  1. Journal Article (3486)
  2. Meeting Abstract (680)
  3. Review (197)
  4. Conference Paper (94)
  5. Book Section (91)
  6. Editorial (90)
  7. Research Letter (34)
  8. Correspondence (25)
  9. Guidelines (23)
  10. Miscellaneous (6)
  11. Book Whole (3)
Groups
  1. Department of Medicine (1520)
  2. Surgery (1224)
  3. Solid Tumor Oncology Division (883)
  4. Survivorship Research (806)
  5. GSK Faculty (664)
  6. Sloan Kettering Institute Faculty (622)

More Groups

People
  1. Harry Herr (91)
  2. Murray Brennan (86)
  3. Robert Motzer (86)
  4. Jatin Shah (77)
  5. Samuel Danishefsky (74)
  6. Ashok Shaha (71)

More People

Years
  1. 2025 (80)
  2. 2024 (195)
  3. 2023 (264)
  4. 2022 (187)
  5. 2021 (221)
  6. 2020 (183)

More Years

Publications
  1. Cancer (1449)
  2. Journal of Surgical Oncology (368)
  3. BJU International (332)
  4. Hematological Oncology (199)
  5. Histopathology (151)
  6. EMBO Journal (131)

More Publications

Results (4729)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Duvelisib in patients with relapsed/refractory peripheral T‐cell lymphoma from the phase 2 PRIMO Trial Expansion Phase: Outcomes by baseline histology
    Meeting Abstract

    Mehta‐Shah, N.; Jacobsen, E. D.; Zinzani, P. L.; Zain, J.; Mead, M.; Casulo, C.; Gritti, G.; Pinter‐Brown, L.; Izutsu, K.; Waters, S.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Efficacy of subcutaneous epcoritamab versus axi‐cel in R/R DLBCL CAR T‐naive and CAR T‐eligible patients: An indirect comparison
    Meeting Abstract

    Thieblemont, C.; Fox, C. P.; Wang, A.; Sail, K.; Alshreef, A.; Moran, M.; Mutebi, A.; Blaedel, J.; Chirikov, V.; Salles, G.
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Predictors of response to radiation therapy and of progression to multiple myeloma in patients with solitary bone and extramedullary plasmacytomas
    Meeting Abstract

    Fregonese, B.; Imber, B.; Lee, J.; Zhang, Z.; Toumbacaris, N.; Yahalom, J.; Hajj, C.
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Radiation in a new era of multiple myeloma management: Patterns of utilization, clinical, radiologic, and biochemical outcomes, and possible genomic correlates of response
    Meeting Abstract

    Dreyfuss, A. D.; Fregonese, B.; Ma, J.; Reith, S.; Cederquist, G.; Hubbeling, H.; Tringale, K. R.; Wijetunga, N. A.; Usmani, S.; Hajj, C.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Five‐year efficacy and safety of tafasitamab in patients with relapsed or refractory DLBCL: Final results from the Phase II L‐MIND study
    Meeting Abstract

    Duell, J.; Abrisqueta, P.; Andre, M.; Augustin, M.; Gaidano, G.; Barca, E. G.; Jurczak, W.; Kalakonda, N.; Liberati, A. M.; Maddocks, K. J.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Five‐year subgroup analysis of tafasitamab + lenalidomide from the phase II L‐MIND study in patients with relapsed or refractory diffuse large B‐cell lymphoma
    Meeting Abstract

    Duell, J.; Abrisqueta, P.; Dreyling, M.; Gaidano, G.; Barca, E. G.; Jurczak, W.; Maddocks, K. J.; Menne, T.; Nagy, Z.; Tournilhac, O.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Tafasitamab plus lenalidomide versus standard of care as second‐line (2L) therapy for patients with R/R DLBCL: A post hoc internal 2L analysis of L‐MIND (IN 2L‐MIND)
    Meeting Abstract

    Sehn, L. H.; Kuruvilla, J.; Salles, G.; Maddocks, K. J.; Koch, C.; Xue, Z.; Amoloja, T.; Amin, A.; Duell, J.
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Patient‐ versus clinician‐reported symptoms in the POLARIX study
    Meeting Abstract

    Thompson, C. A.; Mehta‐Shah, N.; Flowers, C.; Salles, G.; Tilly, H.; Chua, N.; Casasnovas, R.; Miall, F.; Kim, T. M.; Tsai, C.; more...
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • The prognostic value of progressing within 24 months of frontline chemoimmunotherapy (POD24) in relapsed/refractory (R/R) follicular lymphoma (FL)—a SCHOLAR‐5 analysis
    Meeting Abstract

    Patel, A. R.; Limbrick‐Oldfield, E. H.; Kanters, S.; Ray, M. D.; Best, T.; Ghione, P.; Neelapu, S. S.; Gribben, J. G.; Beygi, S.; Bobillo, S.
    Hematological Oncology (2023)

    Fulltext@MSK | Save
  • Patterns of disease failure by response to induction therapy in a large cohort of patients with primary central nervous system lymphoma
    Meeting Abstract

    Tringale, K. R.; Yahalom, J.; Scordo, M.; White, C.; Zhang, Z.; Grommes, C.; Imber, B.
    Hematological Oncology (2023)

    Fulltext@MSK | Save